Benefits of switching from intravenous to subcutaneous daratumumab : perspectives from UK healthcare providers
Cook, Gordon Ashcroft, John Fernandez, Mariana Henshaw, Sarah Khalaf, Zeyad Pratt, Guy Tailor, Anish Rabin, Neil Pratt, Guy Pratt, Guy
Cook, Gordon
Ashcroft, John
Fernandez, Mariana
Henshaw, Sarah
Khalaf, Zeyad
Pratt, Guy
Tailor, Anish
Rabin, Neil
Pratt, Guy
Abstract
Daratumumab is a CD38-directed monoclonal antibody indicated to treat multiple myeloma (MM). Daratumumab was initially administered intravenously (IV), subsequently a subcutaneous (SC) formulation was developed to increase convenience of administration. The UK was an early adopter of SC daratumumab and, as such, this report provides consensus recommendations from a group of UK MM experts, with the aim of facilitating the transition from IV to SC daratumumab for other European healthcare providers. The switch from IV to SC daratumumab has been beneficial to patients and healthcare providers, as it simplifies treatment, reduces pressure on hospitals and can improve patients' quality of life.
MIDER Authors
Citations
Altmetric:
Date
2023-02-23
Type
Article
Subject
Oncology. Pathology., Pharmacology
Collections
Citation
Front Oncol. 2023 Feb 23;13:1063144. doi: 10.3389/fonc.2023.1063144. eCollection 2023
Journal / Source Title
Frontiers in Oncology
DOI
10.3389/fonc.2023.1063144
PMID
36910662
Publisher
Frontiers Media
Publisher’s URL
https://www.frontiersin.org/journals/oncology